Home » Stocks » EMMA

Emmaus Life Sciences, Inc. (EMMA)

Stock Price: $1.45 USD 0.07 (5.07%)
Updated May 13, 2021 3:31 PM EDT - Market closed
Market Cap 68.05M
Revenue (ttm) 23.17M
Net Income (ttm) 1.10M
Shares Out 48.90M
EPS (ttm) -2.09
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day May 13
Last Price $1.45
Previous Close $1.38
Change ($) 0.07
Change (%) 5.07%
Day's Open 1.38
Day's Range 1.20 - 1.50
Day's Volume 5,626
52-Week Range 0.70 - 2.16

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

TORRANCE, Calif., May 4, 2021 /PRNewswire/ -- Emmaus Life Sciences, Inc. (OTC: EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, announced today its...

1 week ago - PRNewsWire

--Meeting Will be Open to the Public-- --Meeting Will be Open to the Public--

8 months ago - GlobeNewsWire

TORRANCE, Calif., Aug. 18, 2020 (GLOBE NEWSWIRE) -- Emmaus Life Sciences, Inc. (OTCPK: EMMA), a leader in sickle cell disease treatment, announced today the submission of an application to the Saudi F...

8 months ago - GlobeNewsWire

TORRANCE, Calif., Aug. 18, 2020 (GLOBE NEWSWIRE) -- Emmaus Life Sciences, Inc. (OTCPK: EMMA), a leader in sickle cell disease treatment, announced today the submission of an application to the Saudi F...

8 months ago - GlobeNewsWire

--Interim Analysis Indicates Decreased Number of Diverticula and Healthy Tissue-- TORRANCE, Calif., Aug. 05, 2020 (GLOBE NEWSWIRE) -- Emmaus Life Sciences, Inc. (OTCPK: EMMA), a leader in sickle cel...

9 months ago - GlobeNewsWire

TORRANCE, Calif, July 31, 2020 (GLOBE NEWSWIRE) -- Emmaus Life Sciences, Inc. (OTCQB: EMMA), a leader in sickle cell disease treatment, provided today additional operational updates for the year ended...

9 months ago - GlobeNewsWire

TORRANCE Calif., July 29, 2020 (GLOBE NEWSWIRE) -- Emmaus Life Sciences, Inc. (OTCQB: EMMA), a leader in sickle cell disease treatment, announced today that the European Medicines Agency (EMA) issued ...

9 months ago - GlobeNewsWire

TORRANCE, Calif., July 23, 2020 (GLOBE NEWSWIRE) -- Emmaus Life Sciences, Inc. (OTCQB: EMMA), a leader in sickle cell disease treatment, announced today the opening of its regional office in Dubai. Th...

9 months ago - GlobeNewsWire

TORRANCE, Calif., July 16, 2020 (GLOBE NEWSWIRE) -- Emmaus Life Sciences, Inc. (OTCQB: EMMA), a leader in sickle cell disease   treatment, is pleased to announce that it has engaged Partner Internatio...

9 months ago - GlobeNewsWire

TORRANCE, Calif., July 08, 2020 (GLOBE NEWSWIRE) -- Emmaus Life Sciences, Inc. (OTCQB: EMMA), a leader in sickle cell disease treatment, today announced it will be restating its previously issued audi...

10 months ago - GlobeNewsWire

TORRANCE, Calif., June 29, 2020 (GLOBE NEWSWIRE) -- Emmaus Life Sciences, Inc. (OTCQB: EMMA), a leader in sickle cell disease treatment, announced today that it was issued a license from the Israeli M...

10 months ago - GlobeNewsWire

Patented Topical Ointment for Treating Skin Ulceration in Sickle Cell Disease and other Indications Patented Topical Ointment for Treating Skin Ulceration in Sickle Cell Disease and other Indications

10 months ago - GlobeNewsWire

Investors look forward to updates on key drug Endari's expansion plans when Emmaus (EMMA) releases fourth-quarter 2019 results.

1 year ago - Zacks Investment Research

About EMMA

Emmaus Life Sciences, Inc. engages in the discovery, development, and commercialization of treatments and therapies primarily for rare and orphan diseases in the United States and internationally. It provides Endari, which is L-glutamine oral powder to reduce the acute complications of sickle cell disease in adult and pediatric patients five years of age and older. Emmaus Life Sciences, Inc. has a collaboration agreement with Kainos Medicine, Inc. for the preclinical development of Kainos' patented IRAK4 inhibitor (KM10544) as an anti-cancer dr... [Read more...]

Industry
Biotechnology
Founded
2000
CEO
Yutaka Niihara
Country
United States
Stock Exchange
OTCMKTS
Ticker Symbol
EMMA
Full Company Profile

Financial Performance

Financial Statements